Patents by Inventor Ehud Arbit

Ehud Arbit has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 10967051
    Abstract: Provided herein are oral pharmaceutical compositions containing a GLP-1 analogue and/or insulin for treating and reducing the incidence of nonalcoholic fatty liver disease (NAFLD), hepatic steatosis, and sequelae thereof, and methods of utilizing same.
    Type: Grant
    Filed: November 19, 2018
    Date of Patent: April 6, 2021
    Assignee: Oramed Ltd.
    Inventors: Miriam Kidron, Ehud Arbit
  • Publication number: 20190380953
    Abstract: This invention provides compositions comprising a protein, an absorption enhancer, a protease inhibitor, method for treating diabetes mellitus, comprising administering same, and methods for oral administration of a protein with an enzymatic activity, comprising orally administering same.
    Type: Application
    Filed: August 21, 2019
    Publication date: December 19, 2019
    Applicant: Entera Bio Ltd.
    Inventors: Miriam KIDRON, Ehud ARBIT
  • Patent number: 10420721
    Abstract: This invention provides compositions comprising a protein, an absorption enhancer, a protease inhibitor, method for treating diabetes mellitus, comprising administering same, and methods for oral administration of a protein with an enzymatic activity, comprising orally administering same.
    Type: Grant
    Filed: June 6, 2018
    Date of Patent: September 24, 2019
    Assignee: Entera Bio Ltd.
    Inventors: Miriam Kidron, Ehud Arbit
  • Publication number: 20190209655
    Abstract: Provided herein are oral pharmaceutical compositions containing a GLP-1 analogue and/or insulin for treating and reducing the incidence of nonalcoholic fatty liver disease (NAFLD), hepatic steatosis, and sequelae thereof, and methods of utilizing same.
    Type: Application
    Filed: November 19, 2018
    Publication date: July 11, 2019
    Applicant: ORAMED LTD.
    Inventors: Miriam Kidron, Ehud Arbit
  • Publication number: 20190022228
    Abstract: This invention relates to microparticles and/or nanoparticles containing a delivery agent and/or an active agent. This invention also relates to pharmaceutical formulations and solid dosage forms, including controlled release solid dosage forms of active agent and a delivery agent.
    Type: Application
    Filed: February 12, 2018
    Publication date: January 24, 2019
    Inventors: George Klein, Shingai Majuru, Puchun Liu, Steven Dinh, Jun Liao, Jongbin Lee, Halina Levchik, Ehud Arbit, Nikhil Dhoot, Jamila Harris, Nai Fang Wang
  • Publication number: 20180280292
    Abstract: This invention provides compositions comprising a protein, an absorption enhancer, a protease inhibitor, method for treating diabetes mellitus, comprising administering same, and methods for oral administration of a protein with an enzymatic activity, comprising orally administering same.
    Type: Application
    Filed: June 6, 2018
    Publication date: October 4, 2018
    Applicant: Entera Bio Ltd.
    Inventors: Miriam KIDRON, Ehud ARBIT
  • Patent number: 10010503
    Abstract: This invention provides compositions comprising a protein, an absorption enhancer, a protease inhibitor, method for treating diabetes mellitus, comprising administering same, and methods for oral administration of a protein with an enzymatic activity, comprising orally administering same.
    Type: Grant
    Filed: November 10, 2015
    Date of Patent: July 3, 2018
    Assignee: Entera Bio Ltd.
    Inventors: Miriam Kidron, Ehud Arbit
  • Publication number: 20180161400
    Abstract: Pharmaceutical dosage forms, comprising insulin, a delivery agent that facilitates insulin transport in a therapeutically effective amount to the bloodstream and a biguanide, such as metformin, are disclosed for oral administration to a patient for the treatment of diabetes.
    Type: Application
    Filed: July 10, 2017
    Publication date: June 14, 2018
    Inventors: Ehud ARBIT, Michael GOLDBERG, Steven DINH
  • Patent number: 9498487
    Abstract: The present invention provides a topical composition comprising (a) at least one delivery agent compound and (b) a cromoglycic acid compound. Methods of treatment, and methods of preparing the topical composition are also provided.
    Type: Grant
    Filed: May 19, 2005
    Date of Patent: November 22, 2016
    Assignee: EMISPHERE TECHNOLOGIES, INC.
    Inventors: Puchun Liu, Steven Dinh, Ehud Arbit, Michael M. Goldberg
  • Publication number: 20160058699
    Abstract: This invention provides compositions comprising a protein, an absorption enhancer, a protease inhibitor, method for treating diabetes mellitus, comprising administering same, and methods for oral administration of a protein with an enzymatic activity, comprising orally administering same.
    Type: Application
    Filed: November 10, 2015
    Publication date: March 3, 2016
    Applicant: ENTERA BIO LTD.
    Inventors: Miriam KIDRON, Ehud ARBIT
  • Publication number: 20150335715
    Abstract: Provided herein are oral pharmaceutical compositions containing a GLP-1 analogue and/or insulin for treating and reducing the incidence of nonalcoholic fatty liver disease (NAFLD), hepatic steatosis, and sequelae thereof and methods of utilizing same.
    Type: Application
    Filed: January 2, 2014
    Publication date: November 26, 2015
    Inventors: Miriam KIDRON, Ehud ARBIT
  • Patent number: 9186412
    Abstract: This invention provides compositions comprising a protein, an absorption enhancer, a protease inhibitor, methods for treating diabetes mellitus, comprising administering same, and methods for oral administration of a protein with an enzymatic activity, comprising orally administering same.
    Type: Grant
    Filed: August 11, 2009
    Date of Patent: November 17, 2015
    Assignee: Entera Bio Ltd.
    Inventors: Miriam Kidron, Ehud Arbit
  • Patent number: 8975227
    Abstract: The present invention provides a composition (e.g., a pharmaceutical composition) comprising at least one delivery agent compound and glucagon. Preferably, the composition includes a therapeutically effective amount of glucagon and the delivery agent compound. The composition of the present invention facilitates the delivery of glucagon and increases its bioavailability compared to administration without the delivery agent compound.
    Type: Grant
    Filed: July 17, 2006
    Date of Patent: March 10, 2015
    Assignee: Emisphere Technologies, Inc.
    Inventors: Nai Fang Wang, Puchun Liu, Steven Dinh, Michael M. Goldberg, Ehud Arbit
  • Patent number: 8962554
    Abstract: Methods for treating impaired glucose tolerance and early and late stage diabetes in mammals, for prophylactically sparing ?-cell function, aiding in preventing ?-cell death, preventing the onset of overt diabetes in a mammal with type 2 diabetes, treating the current level of glycemic control dysfunction of a mammal with impaired glucose tolerance or diabetes, comprising orally administering insulin and a delivery agent that facilitates insulin absorption from the gastrointestinal tract at the time of or shortly before mealtime, e.g., within about 10 minutes prior to ingestion of a meal, on a chronic basis. The methods also comprise, in addition to administering a rapid-acting insulin to provide a first insulin peak, administering a slow acting insulin to provide a second insulin peak occurring at a later time but of a longer duration.
    Type: Grant
    Filed: March 21, 2014
    Date of Patent: February 24, 2015
    Assignee: Emisphere Technologies, Inc.
    Inventors: Ehud Arbit, Michael Goldberg, Shingai Majuru
  • Publication number: 20140206612
    Abstract: Methods for treating impaired glucose tolerance and early and late stage diabetes in mammals, for prophylactically sparing ?-cell function, aiding in preventing ?-cell death, preventing the onset of overt diabetes in a mammal with type 2 diabetes, treating the current level of glycemic control dysfunction of a mammal with impaired glucose tolerance or diabetes, comprising orally administering insulin and a delivery agent that facilitates insulin absorption from the gastrointestinal tract at the time of or shortly before mealtime, e.g., within about 10 minutes prior to ingestion of a meal, on a chronic basis. The methods also comprise, in addition to administering a rapid-acting insulin to provide a first insulin peak, administering a slow acting insulin to provide a second insulin peak occurring at a later time but of a longer duration.
    Type: Application
    Filed: March 21, 2014
    Publication date: July 24, 2014
    Applicant: Emisphere Technologies, Inc.
    Inventors: Ehud ARBIT, Michael GOLDBERG, Shingai MAJURU
  • Patent number: 8729016
    Abstract: Methods for treating impaired glucose tolerance and early and late stage diabetes in mammals, for prophylactically sparing ?-cell function, aiding in preventing ?-cell death, preventing the onset of overt diabetes in a mammal with type 2 diabetes, treating the current level of glycemic control dysfunction of a mammal with impaired glucose tolerance or diabetes, comprising orally administering insulin and a delivery agent that facilitates insulin absorption from the gastrointestinal tract at the time of or shortly before mealtime, e.g., within about 10 minutes prior to ingestion of a meal, on a chronic basis. The methods also comprise, in addition to administering a rapid-acting insulin to provide a first insulin peak, administering a slow acting insulin to provide a second insulin peak occurring at a later time but of a longer duration.
    Type: Grant
    Filed: June 16, 2009
    Date of Patent: May 20, 2014
    Assignee: Emisphere Technologies, Inc.
    Inventors: Ehud Arbit, Michael Goldberg, Shingai Majuru
  • Patent number: 8705823
    Abstract: A breast examination system is disclosed that facilitates normalized quantitative comparison of results from multiple examinations performed under differing conditions, such as different viewing angles. The proposed system can operate on a camera-equipped smart-phone, a camera-equipped desk-top computer, or on a dedicated device to perform a guided breast cancer examination, and then store results of the examination in a normalized format that allows effective quantitative comparison to historic results, thereby detecting changes and trends. The results can be stored on the local device, or on a web-based server, providing various data comparison, data management, and data interpretation services in a secure and controlled manner.
    Type: Grant
    Filed: June 2, 2011
    Date of Patent: April 22, 2014
    Assignee: Newel Dexter LLC
    Inventors: Ziv Harish, Isaac Rubinstein, Ehud Arbit, Russ Weinzimmer
  • Patent number: 8597199
    Abstract: An allergy skin test device is disclosed that causes less pain than commonly used devices that include multi-point sharp puncture heads. The allergy skin test device incorporates multiple dull pressure heads distributed amongst the sharp multi-point sharp puncture heads, each dull pressure head activating a neurological pain gate that reduces pain sensation typically caused by the neighboring multi-point head when it engages the skin.
    Type: Grant
    Filed: October 11, 2010
    Date of Patent: December 3, 2013
    Inventors: Ziv Harish, Isaac Rubinstein, Ehud Arbit, Russ Weinzimmer
  • Publication number: 20130281932
    Abstract: A palm-held device is disclosed for injection of a substance into an organism. The palm-held device has the shape of a computer mouse, and so is very familiar, which helps with ease-of-use and comfort. Like a computer mouse, the device can be moved easily by gently holding and guiding the mouse with the fingers and the palm of the hand. There are many possible button configurations, such as a single button mouse, the button having a large surface at the front top portion of the mouse, and being pressable by any finger. There can also be a two button mouse, such that the left button actuates the injection, and the right button is the “safety” that allows the left button to actuate the injection. The two buttons can be on the top front of the mouse, or can be on the right and left sides of the mouse.
    Type: Application
    Filed: June 19, 2013
    Publication date: October 24, 2013
    Inventors: Ziv Harish, Russ Weinzimmer, Isaac Rubinstein, Ehud Arbit
  • Patent number: RE46823
    Abstract: An allergy skin test device is disclosed that causes less pain than commonly used devices that include multi-point sharp puncture heads. The allergy skin test device incorporates multiple dull pressure heads distributed amongst the sharp multi-point sharp puncture heads, each dull pressure head activating a neurological pain gate that reduces pain sensation typically caused by the neighboring multi-point head when it engages the skin.
    Type: Grant
    Filed: December 3, 2015
    Date of Patent: May 8, 2018
    Inventors: Ziv Harish, Isaac Rubinstein, Ehud Arbit, Russ Weinzimmer